Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.
Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...
Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...
Abhijeet Bhardwaj's commitment to technical excellence and innovation continues to drive successful outcomes in large-scale ...
Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...
In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...
Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...
Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...
Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...
Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...
Becton, Dickinson and Co. (BD) is investing in its U.S. manufacturing network to add capacity for critical medical devices, ...
Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...